|
ESYT2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.07670547425209E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.91749957526122E-11 |
| Normal-vs-Stage2 |
4.45780001800955E-09 |
| Normal-vs-Stage3 |
1.10339515302371E-11 |
| Normal-vs-Stage4 |
1.03830277708994E-11 |
| Stage1-vs-Stage2 |
3.516000E-01 |
| Stage1-vs-Stage3 |
4.060200E-01 |
| Stage1-vs-Stage4 |
3.111400E-01 |
| Stage2-vs-Stage3 |
1.959360E-01 |
| Stage2-vs-Stage4 |
1.556360E-01 |
| Stage3-vs-Stage4 |
7.526000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.3140044607951E-11 |
| Normal-vs-AfricanAmerican |
4.58829999994137E-07 |
| Normal-vs-Asian |
9.00750030119468E-10 |
| Caucasian-vs-AfricanAmerican |
1.651980E-01 |
| Caucasian-vs-Asian |
5.979000E-01 |
| AfricanAmerican-vs-Asian |
4.513800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.30171478835473E-12 |
| Normal-vs-Female |
3.82710529933661E-11 |
| Male-vs-Female |
1.983410E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.25489684888703E-11 |
| Normal-vs-Age(41-60Yrs) |
5.44553291348393E-12 |
| Normal-vs-Age(61-80Yrs) |
7.3880013218286E-11 |
| Normal-vs-Age(81-100Yrs) |
7.644600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.219560E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.475000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.079400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.273000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.257200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.524200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.409200E-01 |
| Classical-VS-Follicular |
6.363800E-01 |
| Classical-VS-Other |
2.217800E-01 |
| Classical-VS-Normal |
1.52210022363874E-10 |
| Tall-VS-Follicular |
3.839600E-01 |
| Tall-VS-Other |
4.658200E-01 |
| Tall-VS-Normal |
3.37490035917654E-11 |
| Follicular-VS-Other |
3.404000E-01 |
| Follicular-VS-Normal |
1.47180045928508E-10 |
| Other-VS-Normal |
1.66299999992958E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11789466572532E-11 |
| Normal-vs-N1 |
1.00159880389583E-11 |
| N0-vs-N1 |
4.423400E-01 |
|
|
